Cognition Therapeutics reports Q3 net loss of $6.7M; updates on Alzheimer’s and DLB trials

COGNITION THERAPEUTICS INC

2023-Q3 EPS reported -$0.59

Net loss of $6.7M ($0.22 per share) in Q3 2023 vs $6.6M ($0.29 per share) in Q3 2022.
Cash and equivalents $33.0M; total grant funds $74.3M from NIA; cash runway through Nov 2024.
Phase 2 SHINE Alzheimer’s topline results expected mid-2024; SHIMMER DLB data also mid-2024.
START trial initiated allowing lecanemab combo therapy; MAGNIFY dry AMD study dosing started.
R&D expenses $11.7M (up 41% YoY); G&A $3.1M (down 30% YoY).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

COGNITION THERAPEUTICS INC reported third quarter ended September 30, 2023 results: net income net loss of $6.7 million, EPS $(0.22) per basic and diluted share.

Period: third quarter ended September 30, 2023
Net income: net loss of $6.7 million
EPS: $(0.22) per basic and diluted share
Result: reported results

Exact text from the filing

The Company reported a net loss of $6.7 million or $(0.22) per basic and diluted share for the third quarter ended September 30, 2023, compared to a net loss of $6.6 million or $(0.29) per basic and diluted share during the same period in 2022.

View on SEC.gov

Browse all earnings releases →

COGNITION THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-113591

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.